PR Newswire: news distribution, targeting and monitoring
Home Page > News Releases > APAC

China Cord Blood Corporation to Report First Quarter Fiscal 2018 Financial Results

2017-08-17 18:40
-Earnings Call Scheduled for 8:00 a.m. ET on August 24, 2017

HONG KONG, Aug. 17, 2017 /PRNewswire/ -- China Cord Blood Corporation (NYSE: CO) (the "Company") today announced that it plans to release its preliminary unaudited first quarter fiscal 2018 financial results on Wednesday, August 23, 2017, after the market close. 

The Company will host a conference call at 8:00 a.m. ET on Thursday, August 24, 2017 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties can access the audio webcast through the Company's IR website at A replay of the webcast will be accessible two hours after the conference call and available for three weeks at the same URL as above. Listeners can also access the call by dialing 1-719-325-2213 or 1-866-564-2842, for US callers, or +852-3008-1527, for Hong Kong callers, access code: 2659383.

Please dial in ten minutes prior to the conference call to ensure proper connection, and be prepared to provide your name and company name to the operator.

Supplemental financial information referenced in the conference call and the first quarter of fiscal 2018 earnings press release will be available at, in the section titled "Investor Center/Press Release", after 4:16 p.m. ET on Wednesday, August 23, 2017, and in the Company's Report on Form 6-K for the month of August 2017, available on the Securities and Exchange Commission's website at  

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.  Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and no new licenses will be granted before 2020 in addition to the seven licenses authorized as of today.  China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services.  For more information, please visit our website at

For more information, please contact:

China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180

ICR, Inc.
William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (646) 405-5185

Source: China Cord Blood Corporation

Related stocks: NYSE:CO

Featured Video

Banking/Financial Service Recent Releases

Biotechnology Recent Releases

Health Care/Hospital Recent Releases

Medical/Pharmaceuticals Recent Releases

Advanced Search
  1. Products & Services
  2. News Releases
  3. Knowledge Center
  4. Journalists & Media
  5. Multimedia Theater
  6. Contact Us